Safety and Efficacy Study of TNX-102 SL in Patients With Military-related PTSD (HONOR)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03062540 |
|
Recruitment Status :
Terminated
(Stopped early due to inadequate separation on primary efficacy endpoint at Week 12 according to Interim Analysis conducted on the first 274 (50%) patients.)
First Posted : February 23, 2017
Last Update Posted : September 17, 2019
|
Sponsor:
Tonix Pharmaceuticals, Inc.
Collaborator:
Premier Research Group plc
Information provided by (Responsible Party):
Tonix Pharmaceuticals, Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
This is a 12-week, multicenter, randomized, double-blind, placebo-controlled, fixed-dose study that will investigate the efficacy and safety of 5.6 mg TNX-102 SL (2 x 2.8 mg tablets)-a sublingual formulation of cyclobenzaprine. Following successful screening and randomization, eligible patients will have a telephonic visit at week 2 and then return regularly to the study clinic for monthly visits for assessments of efficacy and safety.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| PTSD | Drug: TNX-102 SL Drug: Placebo SL Tablet | Phase 3 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 358 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily at Bedtime in Patients With Military-Related PTSD |
| Actual Study Start Date : | March 27, 2017 |
| Actual Primary Completion Date : | July 27, 2018 |
| Actual Study Completion Date : | July 27, 2018 |
Resource links provided by the National Library of Medicine
MedlinePlus related topics:
Veterans and Military Health
| Arm | Intervention/treatment |
|---|---|
|
Experimental: TNX-102 SL Tablet, 2.8 mg
2 x TNX-102 SL, 2.8 mg Tablets taken sublingually each day at bedtime for 12 weeks.
|
Drug: TNX-102 SL
Patients will take 2 tablets of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks
Other Name: Low dose cyclobenzaprine sublingual tablets |
|
Placebo Comparator: Placebo SL Tablet
2 x Placebo Tablet taken sublingually each day at bedtime for 12 weeks.
|
Drug: Placebo SL Tablet
Patients will take 2 tablets of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks
Other Name: Placebo sublingual tablets |
Primary Outcome Measures :
- Mean change from baseline in the total Clinician Administered PTSD Scale (CAPS-5) for DSM-5 at Week 12. [ Time Frame: Day 0, Week 4, Week 8 and Week 12 ]To evaluate the efficacy of the TNX-102 SL (cyclobenzaprine HCl sublingual tablets) using the Clinician Administered PTSD Scale for Diagnostic and Statistical Manual of Mental Disorders (DSM-5) (CAPS-5) total symptom severity score in a 12-week study.
Secondary Outcome Measures :
- Clinical Global Impression - Improvement from Initiation of Treatment (CGI-I) score after 12 weeks of treatment. [ Time Frame: 12 weeks ]To evaluate the efficacy of the TNX-102 SL (cyclobenzaprine HCl sublingual tablets) using the CGI-I score after 12 weeks of treatment.
- Change from baseline in the disruption of social life/leisure activities assessed using the Sheehan Disability Scale (SDS) after 12 weeks of treatment. [ Time Frame: Day 0, Week 4, Week 8 and Week 12. ]To evaluate the efficacy of the TNX-102 SL (cyclobenzaprine HCl sublingual tablets) using the change from baseline in disruption of social life/leisure activities assessed with the SDS after 12 weeks of treatment.
- Change from baseline in the disruption of work/school activities assessed using the Sheehan Disability Scale (SDS) after 12 weeks of treatment. [ Time Frame: Day 0, Week 4, Week 8 and Week 12. ]To evaluate the efficacy of the TNX-102 SL (cyclobenzaprine HCl sublingual tablets) using the change from baseline in disruption of work/school activities assessed with the SDS after 12 weeks of treatment.
- Change from baseline in patients' quality of sleep using the Patient-Reported Outcome Measurement Information System (PROMIS) Sleep Disturbance scale after 12 weeks of treatment. [ Time Frame: Day 0, Week 4, Week 8 and Week 12. ]To evaluate the efficacy of the TNX-102 SL (cyclobenzaprine HCl sublingual tablets) using the change from baseline in quality of sleep using the PROMIS Sleep Disturbance scale after 12 weeks of treatment.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Male or female between 18 and 75 years of age, who have served in any branch of the military.
- Diagnosed with current PTSD as determined by the Clinician-Administered PTSD Scale (CAPS-5) for DSM-5.
- Index trauma(s) resulting in PTSD must meet DSM-5 criterion A for PTSD as described in CAPS-5, have occurred in 2001 or later, be military service related.
- Willing to refrain from use of all other formulations of cyclobenzaprine.
- Willing and able to refrain from antidepressants and other excluded medications.
- Capable of reading and understanding English and able to provide written informed consent.
- If female, either not of childbearing potential or practicing a medically acceptable method of birth control throughout the study.
- Willing and able to comply with all protocol-specified requirements.
Exclusion Criteria:
- Increased risk of suicide, based on the investigator's judgment that is of a severity that is not appropriate for outpatient management, or that warrants additional therapy excluded by the protocol.
- Significant (e.g., moderate or severe) comorbid traumatic brain injury (TBI) by history.
- Severe depressive symptoms at screening or baseline.
- Clinically significant laboratory abnormalities based on screening laboratory tests and/or medical history in the investigator's opinion.
- Use of antidepressant medication within 2 months of baseline.
- Female patients who are pregnant or lactating.
- History of serotonin syndrome, severe allergic reaction or bronchospasm or known hypersensitivity to cyclobenzaprine or the excipients.
- Seizure disorder.
- Patients with a body mass index (BMI) > 45.
- Has received any other investigational drug within 30 days before Screening.
- Previous participation in any other study with TNX-102 SL.
- Family member of investigative staff.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03062540
Locations
Show 43 study locations
Sponsors and Collaborators
Tonix Pharmaceuticals, Inc.
Premier Research Group plc
Investigators
| Study Director: | Greg Sullivan, MD | Tonix Pharmaceuticals |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Tonix Pharmaceuticals, Inc. |
| ClinicalTrials.gov Identifier: | NCT03062540 |
| Other Study ID Numbers: |
TNX-CY-P301 |
| First Posted: | February 23, 2017 Key Record Dates |
| Last Update Posted: | September 17, 2019 |
| Last Verified: | September 2019 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Undecided |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Keywords provided by Tonix Pharmaceuticals, Inc.:
|
PTSD Military-related PTSD |
Additional relevant MeSH terms:
|
Stress Disorders, Post-Traumatic Stress Disorders, Traumatic Trauma and Stressor Related Disorders Mental Disorders Cyclobenzaprine Antidepressive Agents, Tricyclic Antidepressive Agents |
Psychotropic Drugs Muscle Relaxants, Central Physiological Effects of Drugs Neuromuscular Agents Peripheral Nervous System Agents Tranquilizing Agents Central Nervous System Depressants |